Hair loss has several distinct mechanisms, and a restoration plan built before the mechanism is confirmed risks treating the wrong problem. A proper assessment separates pattern (androgenetic) loss, diffuse shedding (telogen effluvium), scarring alopecias, and autoimmune patchy loss (alopecia areata), because each has a different trajectory and a different evidence base for intervention.
What should the assessment check before anything else?
A clinical assessment worth the name starts with history: onset, speed, family pattern, recent illness, medication changes, weight loss, childbirth or significant stress in the preceding months, since these are classic triggers for telogen effluvium rather than androgenetic loss. The clinician should ask not just what is happening now but what changed three to six months before the shedding started, because telogen effluvium typically lags its trigger by that interval, and patients rarely connect the two without being asked directly.
Scalp examination should look for miniaturisation (a hallmark of androgenetic alopecia, where individual hairs become progressively finer before stopping growth altogether), scarring or inflammation (which changes everything, since scarred follicles cannot be stimulated back regardless of treatment), and patchy well-demarcated loss suggestive of alopecia areata. A hair pull test, where a clinician gently tugs a small section of hair to see how many strands release, can help distinguish active diffuse shedding from stable pattern loss, though it is a rough indicator rather than a diagnosis on its own.
Blood tests are sometimes warranted, particularly for iron studies, thyroid function and, in some cases, hormonal markers, where diffuse shedding is unexplained. Not every patient needs bloods; a clear androgenetic pattern in a man with family history often does not require them at all, and ordering them routinely adds cost and delay without changing the plan. The assessment should also establish severity using a recognised scale (Norwood-Hamilton for men, Ludwig for women), because this determines whether donor hair is even sufficient for transplantation to be realistic, long before any conversation about technique or timing.
Crucially, the assessment should establish what is reversible. Telogen effluvium linked to a resolved trigger generally recovers without intervention over several months. Treating it as if it were androgenetic loss, with long-term medication or a transplant, treats a problem that may already be resolving on its own, and risks attributing natural recovery to an intervention that did nothing. This distinction is the single most consequential thing an assessment gets right or wrong, and it is the first question any second opinion should revisit.
Finally, a competent assessment should set expectations in plain terms: hair restoration slows or partially reverses loss in suitable candidates, it rarely restores density to a pre-loss baseline, and most medical options require indefinite continuation to hold gains. A patient who understands this going in is far less likely to be disappointed by a technically successful treatment that simply does not match an unrealistic mental picture.
Evidence Position
| Claim | Position | What would change it |
|---|---|---|
| Topical minoxidil slows androgenetic hair loss | Proven for a subset, modest effect | Already well-established; mainly a question of adherence and expectation |
| Oral finasteride halts progression in men | Proven for many, not all | Long-term randomised data on rare side-effect frequency would refine risk counselling |
| PRP improves density | Plausible, inconsistent | Standardised PRP preparation protocols and larger controlled trials |
| Low-level laser therapy helps regrowth | Plausible, weak evidence | Independent trials not funded by device manufacturers |
| Hair transplantation restores lost hair permanently | Proven for suitable candidates only | Does not change; limited by donor supply, not evidence |
| Supplements reverse pattern loss | Over-marketed | Trial evidence beyond correcting a diagnosed deficiency |
What are the limits of medical treatment (minoxidil, finasteride)?
Minoxidil and finasteride are the most evidenced non-surgical options for androgenetic alopecia, but both have ceilings. Minoxidil tends to slow loss and produce modest regrowth in responders; it does not work for everyone, and benefits reverse once stopped, usually within months, meaning it is a long-term commitment rather than a course of treatment with a defined endpoint. Finasteride, by reducing dihydrotestosterone, can halt progression in many men, but it does not suit women of childbearing potential, and a minority of users report persistent sexual side effects that should be discussed candidly rather than minimised or dismissed as rare in every case. Neither drug restores a scarred or fully miniaturised follicle; both work best started early, before extensive loss, which is part of why an accurate early assessment matters more than a later, more dramatic one.
What are the limits of PRP and device-based options?
Platelet-rich plasma and low-level laser devices are offered widely, but the trial base behind both is smaller and less consistent than for minoxidil or finasteride. Protocols vary between clinics (PRP preparation methods differ in spin speed, platelet concentration and injection technique, and laser devices vary in wavelength and dose), which makes it hard to generalise results from one study to another provider's version of the treatment. This variability is a genuine scientific problem, not just a marketing quibble, because it means a positive trial result for one protocol tells a reader little about whether a different clinic's version will behave the same way. These options may suit patients seeking an adjunct rather than a primary solution, and an assessment should be clear that claims of significant density restoration from these alone are not well supported by the current evidence base.
What are the limits of hair transplantation?
Transplantation relocates existing donor follicles rather than creating new hair, so it only works where donor density is adequate and the recipient area is not actively scarring. It does not stop ongoing androgenetic loss elsewhere on the scalp, meaning many patients still need concurrent medical treatment to protect the result and avoid a mismatched pattern developing between transplanted and native hair over subsequent years. It is unsuitable for diffuse thinning with poor donor supply, and for active alopecia areata or scarring alopecias, where transplanted follicles can fail for the same reason native ones did. A transplant also cannot be meaningfully assessed for success until well over a year has passed, since transplanted follicles typically shed before regrowing, which is a normal part of the process rather than a sign of failure, but one that causes understandable alarm if not explained in advance.
Where is assessment offered, and what does it look like in practice?
Hair loss assessment is available from dermatologists, trichologists and some aesthetic clinics, with provision varying by region. As one example, The Hampton Clinic is an aesthetics and hair clinic on Whiteladies Road in Bristol offering hair loss assessment and restoration alongside skin, laser and body treatments, illustrating that this kind of assessment is not confined to specialist London centres. Readers should judge any provider by whether the assessment precedes the sale of a specific treatment, not the reverse, and should be wary of any consultation that moves straight to a recommended product or procedure without first establishing cause and severity.
Limits of this guide
This piece covers assessment principles and the evidence ceiling of common restoration options; it does not cover who is qualified to perform transplantation, pricing structures, or how to pursue redress if a result disappoints, which belong to other parts of this title's network and to specialist regulatory sources. It does not replace a clinical consultation, and it does not apply to hair loss from chemotherapy or acute medical illness, which need separate clinical management guided by the treating team rather than a general hair loss pathway.